Advocacy intelligence hub — real-time data for patient organizations
Stanford University — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Xalkori
Pfizer, Inc.
Xalkori
(crizotinib)Orphan drugstandardPfizer, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 ...
Browse all ALK-positive anaplastic large cell lymphoma news →
Matthew Krebs, Dr
The Christie Hospital
Alex F Herrera
City of Hope Medical Center
Mitchell S Cairo, MD, MD
New York Medical College
📍 HAWTHORNE, NY
David SIBON, MD
Hôpital Necker-Enfants Malades
Eric J Lowe
Children's Oncology Group
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
View all ALK-positive anaplastic large cell lymphoma specialists →